地特胰岛素与中性鱼精蛋白胰岛素在妊娠期糖尿病中的比较效果随机对照试验
本研究为多中心随机对照试验,纳入108例2型或显性2型糖尿病(妊娠<20周诊断)的单胎孕妇,比较地特胰岛素与中性鱼精蛋白胰岛素(NPH)对不良新生儿结局复合指标的影响。贝叶斯分析显示地特胰岛素组主要结局降低的后验概率为87%(后验调整相对风险0.88,95%可信区间0.61-1.12),母体低血糖事件和高血压疾病也呈一致获益趋势。
要点
- 地特胰岛素较NPH降低不良新生儿结局复合指标的后验概率为87%。
- 地特胰岛素组母体低血糖事件获益概率97%,后验调整相对风险0.59。
- 地特胰岛素组妊娠期高血压疾病获益概率88%,后验调整相对风险0.81。
核心结论
- 在2型或显性2型糖尿病孕妇中,地特胰岛素较NPH降低了不良新生儿和母体结局的发生率。
研究设计与样本
- 多中心随机对照试验,2018年9月至2020年1月,纳入108例妊娠≤21周的单胎2型或显性2型糖尿病孕妇,随机分为地特胰岛素组(57例)和NPH组(51例),主要结局分析可用103例。
主要发现
- 地特胰岛素组主要结局降低的后验概率为87%,后验调整相对风险0.88(95%可信区间0.61-1.12)。
- 母体低血糖事件获益概率97%,后验调整相对风险0.59(95%可信区间0.29-1.08)。
- 妊娠期高血压疾病获益概率88%,后验调整相对风险0.81(95%可信区间0.54-1.16)。
关键数值与推荐
- 主要结局为不良新生儿结局复合指标,包括肩难产、大于胎龄儿、新生儿重症监护室入住、呼吸窘迫或低血糖。
- 样本量108例基于贝叶斯统计,假设80%把握度、地特胰岛素降低主要结局33%的效应,>75%概率检测到任何降低。
临床怎么用
- 对于2型或显性2型糖尿病孕妇,地特胰岛素可作为NPH的替代选择以降低不良新生儿和母体结局风险。
局限性
- 主要结局和母体结局的可信区间均包含1,结果需谨慎解读。
- 样本量较小(108例),5例在24周前妊娠丢失未纳入主要结局分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insulin detemir, being used increasingly during pregnancy, may have pharmacologic benefits compared with neutral protamine Hagedorn. OBJECTIVE: We evaluated the probability that compared with treatment with neutral protamine Hagedorn, treatment with insulin detemir reduces the risk for adverse neonatal outcome among individuals with type 2 or overt type 2 diabetes mellitus (gestational diabetes mellitus diagnosed at <20 weeks' gestation). STUDY DESIGN: We performed a multiclinic randomized controlled trial (September 2018 to January 2020), which included women with singleton gestation with type 2 or overt type 2 diabetes mellitus who sought obstetrical care at ≤21 weeks' gestation. Participants were randomized to receive either insulin detemir or neutral protamine Hagedorn by a clinic-stratified scheme. The primary outcome was a composite of adverse neonatal outcomes, including shoulder dystocia, large for gestational age, neonatal intensive care unit admission, respiratory distress (defined as the need of at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure or ventilation at the first 24 hours of life), or hypoglycemia. The secondary neonatal outcomes included gestational age at delivery, small for gestational age, 5-minute Apgar score of <7, lowest glucose level, need for intravenous glucose, respiratory distress syndrome, need for mechanical ventilation or continuous positive airway pressure, neonatal jaundice requiring therapy, brachial plexus injury, and hospital length of stay. The secondary maternal outcomes included hypoglycemic events, hospital admission for glucose control, hypertensive disorder of pregnancy, maternal weight gain, cesarean delivery, and postpartum complications. We used the Bayesian statistics to estimate a sample size of 108 to have >75% probability of any reduction in the primary outcome, assuming 80% power and a hypothesized effect of 33% reduction with insulin detemir. All analyses were intent to treat under a Bayesian framework with neutral priors (a priori assumed a 50:50 likelihood of either intervention being better; National Clinical Trial identifier 03620890). RESULTS: There were 108 women randomized in this trial (57 in insulin detemir and 51 in neutral protamine Hagedorn), and 103 women were available for analysis of the primary outcome (n=5 for pregnancy loss before 24 weeks' gestation). Bayesian analysis indicated an 87% posterior probability of reduced primary outcome with insulin detemir compared with neutral protamine Hagedorn (posterior adjusted relative risk, 0.88; 95% credible interval, 0.61-1.12). Bayesian analyses for secondary outcomes showed consistent findings of lower adverse maternal outcomes with the use of insulin detemir vs neutral protamine Hagedorn: for example, maternal hypoglycemic events (97% probability of benefit; posterior adjusted relative risk, 0.59; 95% credible interval, 0.29-1.08) and hypertensive disorders (88% probability of benefit; posterior adjusted relative risk, 0.81; 95% credible interval, 0.54-1.16). CONCLUSION: In our comparative effectiveness trial involving individuals with type 2 or overt type 2 diabetes mellitus, use of insulin detemir resulted in lower rates of adverse neonatal and maternal outcomes compared with neutral protamine Hagedorn.
引用
- Fishel Bartal M, Ward C, Blackwell SC, et al. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. Am J Obstet Gynecol. 2021. PMID: 33865836. doi:10.1016/j.ajog.2021.04.223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。